{"filing":{"accession_number":"0000012208-26-000046","cik":"0000012208","ticker":"BIO-B","company_name":"BIO-RAD LABORATORIES, INC.","form":"8-K","filing_date":"2026-08-04","report_date":"2026-07-31","primary_document":"bio-20260731.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/12208/000001220826000046/bio-20260731.htm"},"events":[{"id":23768,"run_id":21497,"accession_number":"0000012208-26-000046","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Bio-Rad announced its second-quarter 2026 financial results on August 4, 2026, disclosing net sales of $651.0 million (flat year-over-year), net income of $371.4 million ($13.85 per diluted share), and operating cash flow of $98.7 million, with detailed segment performance and full-year 2026 guidance.","company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO-B","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24094,"accession_number":"0000012208-26-000046","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Bio-Rad announced its second-quarter 2026 financial results on August 4, 2026, disclosing net sales of $651.0 million (flat year-over-year), net income of $371.4 million ($13.85 per diluted share), and operating cash flow of $98.7 million. The press release includes detailed segment performance, full-year 2026 guidance, and reconciliation of GAAP to non-GAAP measures. This is a standard quarterly earnings disclosure furnished as Exhibit 99.1 under Item 2.02, material to investors assessing the company's operational and financial performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:15:29.000983+00:00","company_name":"","ticker":null,"filing_date":""},{"id":24096,"accession_number":"0000012208-26-000046","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Bio-Rad disclosed its second-quarter 2026 financial results via press release on August 4, 2026, reporting net sales of $651.0 million (flat year-over-year), net income of $371.4 million ($13.85 per diluted share), and reaffirming full-year 2026 guidance. The filing includes detailed GAAP and non-GAAP financial statements, segment performance, and management commentary from CEO Norman Schwartz. This is a standard quarterly earnings release disclosed under Item 7.01 (Regulation FD Disclosure) with exhibits containing the press release and supplemental presentation materials.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:15:29.000983+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":23769,"run_id":21497,"accession_number":"0000012208-26-000046","anchor_item_number":"2.05","event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"Bio-Rad initiated a strategy-driven restructuring plan on July 31, 2026, involving elimination of positions, consolidation of functions, and facility closures worldwide, with estimated pre-tax charges of $80–$90 million primarily for termination benefits, severance, and healthcare, expected to complete by end of fiscal 2027.","company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO-B","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24095,"accession_number":"0000012208-26-000046","item_number":"2.05","item_title":"Costs Associated with Exit or Disposal Activities","event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Item 2.05 discloses a strategy-driven restructuring plan initiated on July 31, 2026, involving elimination of positions, consolidation of functions, and facility closures worldwide. Bio-Rad estimates $80–$90 million in pre-tax charges, primarily for termination benefits, severance, and healthcare. The restructuring is expected to complete by end of fiscal 2027. This is a classic workforce reduction with associated exit costs under Item 2.05, material to investors assessing operational and financial performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:15:29.000983+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24094,"accession_number":"0000012208-26-000046","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Bio-Rad announced its second-quarter 2026 financial results on August 4, 2026, disclosing net sales of $651.0 million (flat year-over-year), net income of $371.4 million ($13.85 per diluted share), and operating cash flow of $98.7 million. The press release includes detailed segment performance, full-year 2026 guidance, and reconciliation of GAAP to non-GAAP measures. This is a standard quarterly earnings disclosure furnished as Exhibit 99.1 under Item 2.02, material to investors assessing the company's operational and financial performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:15:29.000983+00:00","company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO-B","filing_date":"2026-08-04"},{"id":24095,"accession_number":"0000012208-26-000046","item_number":"2.05","item_title":"Costs Associated with Exit or Disposal Activities","event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Item 2.05 discloses a strategy-driven restructuring plan initiated on July 31, 2026, involving elimination of positions, consolidation of functions, and facility closures worldwide. Bio-Rad estimates $80–$90 million in pre-tax charges, primarily for termination benefits, severance, and healthcare. The restructuring is expected to complete by end of fiscal 2027. This is a classic workforce reduction with associated exit costs under Item 2.05, material to investors assessing operational and financial performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:15:29.000983+00:00","company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO-B","filing_date":"2026-08-04"},{"id":24096,"accession_number":"0000012208-26-000046","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Bio-Rad disclosed its second-quarter 2026 financial results via press release on August 4, 2026, reporting net sales of $651.0 million (flat year-over-year), net income of $371.4 million ($13.85 per diluted share), and reaffirming full-year 2026 guidance. The filing includes detailed GAAP and non-GAAP financial statements, segment performance, and management commentary from CEO Norman Schwartz. This is a standard quarterly earnings release disclosed under Item 7.01 (Regulation FD Disclosure) with exhibits containing the press release and supplemental presentation materials.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:15:29.000983+00:00","company_name":"BIO-RAD LABORATORIES, INC.","ticker":"BIO-B","filing_date":"2026-08-04"}]}